Research programme: congestive heart failure-gene therapy - Sanofi Genzyme

Drug Profile

Research programme: congestive heart failure-gene therapy - Sanofi Genzyme

Alternative Names: Vascular graft occlusion gene therapy - Sanofi Genzyme; βARKct gene therapy

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Duke University; Genzyme Corporation
  • Class
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ischaemic heart disorders; Vascular graft occlusion

Most Recent Events

  • 22 Jun 2005 Preclinical trials in Vascular graft occlusion in USA (unspecified route)
  • 22 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the adverse events and Ischaemic heart disease pharmacodynamics section
  • 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top